Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of S-005151 in chronic liver disease
jRCT2031200232Phase 2Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Dec 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of redasemtide in chronic liver disease (CLD) and Cirrhosis (2 cohorts), sponsored by Shionogi & Co., Ltd. Primary endpoint: Number of adverse events during the S-005151 administration period and 14 days post-observation. Started Dec 2020; status: completed.
02
Drugs
redasemtide
03
Conditions
chronic liver disease (CLD)Cirrhosis
Beyond the preview
Go deeper on jRCT2031200232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200232.